Sun Pharmaceutical Industries, Inc. inks icensing agreement with Aclaris Therapeutics, Inc

Sun Pharmaceutical Industries, Inc., a subsidiary of Sun Pharmaceutical Industries Limited, has entered into licensing agreement with Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases.

Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1240.10 as compared to the previous close of Rs. 1231.45. The total number of shares traded during the day was 77170 in over 5216 trades.

The stock hit an intraday high of Rs. 1242.00 and intraday low of 1221.10. The net turnover during the day was Rs. 95141419.00.

Source : Equity Bulls

Keywords

SunPharmaceuticalIndustries INE044A01036 LicesingAgreement AclarisTherapeutics